Haverford Trust Co Has $9.32 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Haverford Trust Co trimmed its position in Kenvue Inc. (NYSE:KVUE) by 1.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 436,417 shares of the company’s stock after selling 4,736 shares during the period. Haverford Trust Co’s holdings in Kenvue were worth $9,318,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Handelsbanken Fonder AB raised its holdings in Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after acquiring an additional 21,222 shares in the last quarter. Alberta Investment Management Corp raised its position in Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock valued at $12,445,000 after purchasing an additional 109,700 shares during the last quarter. Longbow Finance SA lifted its position in shares of Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock worth $5,990,000 after purchasing an additional 13,287 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Kenvue by 143.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company’s stock worth $1,023,000 after buying an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. raised its position in shares of Kenvue by 1.4% during the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock worth $26,754,000 after acquiring an additional 17,466 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Kenvue stock opened at $23.34 on Monday. The stock has a 50-day moving average price of $22.08 and a two-hundred day moving average price of $22.43. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $44.61 billion, a PE ratio of 44.04, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on KVUE shares. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Barclays reduced their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, UBS Group dropped their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average price target of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.